Biotech Values

[jbog]

Some rainy day it would be interesting to see if Enta's contract with Abbvie will be a good agreement or not.

On one hand, their milestones have been fantastic and have built a great balance sheet. On the other hand, the way they booked the income, it has brought taxation into play and made the government a winner.

I think the stock action this week is partly to blame on the minuscule royalty payment for a drug that's on a current run rate of $2 Bil.

In my view it partly explains why Abbvie sold their holdings.